L2 Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.22M Sell
66,161
-4,759
-7% -$666K 0.88% 31
2025
Q4
$8.7M Buy
70,920
+10,200
+17% +$1.24M 1.16% 18
2025
Q3
$6.74M Buy
60,720
+4,204
+7% +$478K 0.98% 29
2025
Q2
$6.27M Buy
56,516
+28,592
+102% +$3.04M 1.03% 24
2025
Q1
$3.13M Buy
27,924
+23,117
+481% +$2.39M 0.64% 53
2024
Q4
$444K Sell
4,807
-118
-2% -$10.6K 0.1% 143
2024
Q3
$413K Sell
4,925
-6,171
-56% -$471K 0.11% 132
2024
Q2
$761K Sell
11,096
-9,500
-46% -$634K 0.23% 84
2024
Q1
$1.51M Buy
20,596
+5,852
+40% +$450K 0.5% 55
2023
Q4
$1.19M Buy
14,744
+10,512
+248% +$818K 0.49% 56
2023
Q3
$1.73M Sell
4,232
-54,287
-93% -$4.18M 0.81% 39
2023
Q2
$4.56M Sell
58,519
-166
-0.3% -$13.2K 2.23% 5
2023
Q1
$4.87M Buy
58,685
+3,238
+6% +$268K 2.68% 6
2022
Q4
$4.76M Buy
55,447
+344
+0.6% +$27.2K 2.96% 6
2022
Q3
$3.4M Buy
55,103
+5,115
+10% +$323K 2.34% 9
2022
Q2
$3.09M Buy
49,988
+15,970
+47% +$989K 2.24% 8
2022
Q1
$2.02M Buy
34,018
+14,649
+76% +$936K 1.16% 28
2021
Q4
$1.41M Buy
19,369
+16,216
+514% +$1.12M 0.98% 37
2021
Q3
$220K Sell
3,153
-6,296
-67% -$442K 0.56% 55
2021
Q2
$651K Sell
9,449
-8,964
-49% -$599K 0.6% 57
2021
Q1
$1.19M Sell
18,413
-2,435
-12% -$157K 1.23% 35
2020
Q4
$1.22M Sell
20,848
-6,293
-23% -$380K 0.83% 37
2020
Q3
$1.72M Buy
27,141
+772
+3% +$53.5K 1.38% 28
2020
Q2
$2.03M Sell
26,369
-8,362
-24% -$641K 1.84% 22
2020
Q1
$2.6M Buy
34,731
+13,910
+67% +$961K 2.91% 11
2019
Q4
$1.35M Buy
+20,821
New +$1.36M 1.19% 38

Other funds holding GILD

L2 Asset Management's GILD Position: Q1 2026 in Review

L2 Asset Management reduced its Gilead Sciences (GILD) stake by 6.7% in Q1 2026, selling an estimated $666K and leaving 66,161 shares worth $9.22M. The position accounts for 0.88% of the portfolio, ranked #31.

L2 Asset Management first reported a position in GILD in Q4 2019 and has held it in 26 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • L2 Asset Management held 66,161 shares of Gilead Sciences worth $9.22M as of Q1 2026.
  • L2 Asset Management sold 4,759 Gilead Sciences shares in Q1 2026, an estimated $666K.
  • Gilead Sciences made up 0.88% of L2 Asset Management's portfolio in Q1 2026, its #31 holding.
  • L2 Asset Management first reported a position in Gilead Sciences in Q4 2019 and has held it in 26 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on L2 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.